Screener
Aquestive Therapeutics, Inc. AQST Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfDebt.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of warrants under the Credit Agreement | 663 | — |
| Proceeds from shares issued under employee stock purchase plan | 70 | 50 |
| Proceeds from exercise of stock options, net | 27 | 7 |
| Repayment of debt principal - 13.5% Notes | (45,000) | — |
| Debt exit fee paid - 13.5% Notes | (2,000) | — |
| Premium paid to retire debt - 13.5% Notes | (3,887) | — |
| Payments for financing costs | (3,470) | — |
| Payments for lease liabilities | (18) | (14) |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s debt repayments?
- Aquestive Therapeutics, Inc. (AQST) reported debt repayments of $44.99M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s debt repayments changed year-over-year?
- Aquestive Therapeutics, Inc.'s debt repayments increased by 749966.7% year-over-year, from -$6K to $44.99M.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Aquestive Therapeutics, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude